Register entry
- Registered sites
- 0
- Active NDC listings
- 13
- Live patents
- 3
- Exclusivities
- 1
- Countries
- 0
Catalogue
Drug listings by form and route
1313 active NDC listings: 13 human prescription drug. By marketing category: ANDA 11, NDA 1, UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE 1.
| Dosage form | NDCs |
|---|---|
| injection | 5 |
| injection, powder, lyophilized, for solution | 5 |
| injection, solution | 3 |
| Route | NDCs |
|---|---|
| intravenous | 13 |
| intramuscular | 1 |
| subcutaneous | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| provepharm inc. | 13 |
Exclusivity
Patents and exclusivities
3| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 11845867 | BLUDIGOindigotindisulfonate sodium | substance | Nov 2036 |
| 10927258 | BLUDIGOindigotindisulfonate sodium | substance | Dec 2037 |
| 11499050 | BLUDIGOindigotindisulfonate sodium | substance | Dec 2037 |
| Product | Exclusivity | Until |
|---|---|---|
| BLUDIGOINDIGOTINDISULFONATE SODIUM | NCE New chemical entity | Jul 2027 |
Catalogue
Marketed products
13| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| ANTICHOLIUM | physostigmine salicylate | injection, intravenous | 81284-831UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE |
| BLUDIGO | indigotindisulfonate sodium | injection, intravenous | 81284-315NDA |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | injection, solution, intramuscular, intravenous, subcutaneous | 81284-411ANDA |
| PIPERACILLIN AND TAZOBACTAM | Piperacillin sodium and Tazobactam sodium | injection, powder, lyophilized, for solution, intravenous | 81284-151ANDA |
| PIPERACILLIN AND TAZOBACTAM | Piperacillin sodium and Tazobactam sodium | injection, powder, lyophilized, for solution, intravenous | 81284-152ANDA |
| PIPERACILLIN AND TAZOBACTAM | Piperacillin sodium and Tazobactam sodium | injection, powder, lyophilized, for solution, intravenous | 81284-153ANDA |
| Phenylephrine hydrochloride | Phenylephrine hydrochloride | injection, intravenous | 81284-211ANDA |
| Phenylephrine hydrochloride | Phenylephrine hydrochloride | injection, intravenous | 81284-212ANDA |
| Phenylephrine hydrochloride | Phenylephrine hydrochloride | injection, intravenous | 81284-213ANDA |
| Piperacillin and Tazobactam | Piperacillin sodium and Tazobactam sodium | injection, powder, lyophilized, for solution, intravenous | 81284-154ANDA |
| Piperacillin and Tazobactam | Piperacillin sodium and Tazobactam sodium | injection, powder, lyophilized, for solution, intravenous | 81284-155ANDA |
| tranexamic acid | Tranexamic Acid | injection, solution, intravenous | 81284-611ANDA |
| tranexamic acid | Tranexamic Acid | injection, solution, intravenous | 81284-612ANDA |
Enquiry
Common questions
- Is Provepharm Inc. FDA approved?
- Provepharm Inc. holds no registered establishment of its own; 13 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Provepharm Inc. make?
- 13 products are listed under Provepharm Inc. in the openFDA NDC Directory, most often as injection; injection, powder, lyophilized, for solution; injection, solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.